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Introduction involved knitted Dacron that required preclotting. The
antibiotic mixture was added to the blood used for
Despite routine antibiotic prophylaxis, graft infection preclotting in the hope that it would remain in the
graft interstices. Subsequently it was realised that aoccurs after 3–5% of all prosthetic vascular re-
constructions.1 The complication is a major burden to ligand would be necessary to bind the antibiotic to
the graft. Various attempts were made, principallyvascular surgeons and their patients, with significant
time and cost implications.2 Management can be dif- in North America, using several different surfactants
including benzalkonium chloride and silver-allantoinficult and the outcome is often disappointing. Recent
research interest has focused on attempts to develop to provide non-covalent bonding directly to the graft
surface.3 More recently, coated grafts have been de-an infection-resistant prosthetic graft, principally by
impregnating antibiotic onto its surface. veloped to prevent leakage of blood through the graft
fabric. It has been possible to attach antibiotic to the
collagen coat of a Dacron graft using ligands such as
triodecylmethylammonium chloride.4 Despite ex-
Infection-resistant Graft: Theoretical Aspects perimental work detailing their potential benefit, these
attempts to create an off-the-shelf antibiotic graft have
It is believed that most graft infection is the result of proved cumbersome and expensive.
implantation of pathogenic bacteria at, or soon after, Many surgeons presently employ coated Dacron
the time of surgery. Contamination may be hidden grafts that have been developed to prevent interstitial
underneath a healed wound, or perhaps more often, bleeding. Recently it has been shown that antibiotic
the result of progression of a local wound infection to can attach to the surface coating of these Dacron grafts
involve the graft fabric (one reason why the aetiology by simple passive diffusion. Although less effective in
of wound and graft infections are similar). A theoretical collagen, rifampicin has been shown to bind to the
way to reduce the rate of graft infection is to im- gelatin coating of a Dacron graft to produce the first
pregnate the graft fabric with an antibiotic (or anti- impregnated graft suitable for large scale clinical tri-
septic) to prevent bacterial adherence.3 The concept of als.5,6
antibiotic impregnation of vascular grafts has been
espoused for almost two decades and this report re-
views the progress with this technology. One reason
for the slow progress is that licensing authorities have The Rifampicin-bonded Graft
regarded novel off-the-shelf antibiotic bonded grafts
as a new device and required formal trials for re- The combination of an existing graft with a licensed
antibiotic has the most immediate promise for pro-gistration.3
Initial attempts to create an infection-resistant graft gress. The addition of rifampicin to a gelatin-coated
1078–5884/00/110409+04 $35.00/0  2000 Harcourt Publishers Ltd.
J. J. Earnshaw410
Table 1. Theoretical requirements in an antibiotic-impregnated graft.
Theoretical Evidence
Rifampicin-bonded gelatin-coated Dacron
1. In vitro adherence Rifampicin bonds in test tube conditions (does to
most coated Dacron grafts)5–7
2. In vivo adherence Sheep carotid Dacron model: rifampicin present
up to 72 h, resists bacterial challenge7,9
Porcine model of aortic Dacron graft: rifampicin
detected on graft for 72 h, in perigraft fluid for
24 h, but not in serum8
3. In vivo activity Porcine model of aortic Dacron graft: rifampicin
graft has reduced infection rate after bacterial
challenge8
Canine thoracoabdominal aortic bypass model:
resisted intravenous bacterial challenge 48 h after
insertion10
Sheep carotid artery model: rifampicin protected
graft to S. aureus challenge11
Clinical evidence that rifampicin still present on
graft in patient who died 22 days after insertion12
4. Clinical effects Randomised trials (see Table 2)
Dacron graft (Gelsoft/Gelseal, Sulzer Vascutek Ltd) is Clinical Results with Rifampicin-bonded Dacron
Graftspresently available and has had the largest clinical and
research interest. The published clinical results with
There have been three randomised controlled trials ofthis graft are outlined below, partly to analyse its
clinical role, and partly to establish a model for future rifampicin-bonded Dacron grafts.13–16 The first was the
Italian study involving 600 patients having aorto-investigation of novel impregnated grafts.
The ideal properties of an antibiotic impregnated femoral grafts,13 the second European study included
2400 patients with aortofemoral or femorofemoralgraft are not known. For instance, it is not clear whether
the antibiotic should be bound tightly to the graft in grafts,14 and the third Joint Vascular Research Group
trial involved 250 patients having extra-anatomic by-high concentration or whether it should be released
in controlled fashion into perigraft tissues. The optimal pass.15,16 The European trial did not report late results.
Disappointingly, neither of the two studies reportingduration of attachment and the best antibiotic (broad
or narrow spectrum) and concentration are not known, 2-year results showed a significant reduction in graft
infections with rifampicin (Table 2). Two studies re-but common sense suggests the antibiotic should be
present for several days and have activity against the ported reductions in the total early wound and graft
infection rates, though these were statistically in-common pathogens causing graft infection. These may
vary in individual hospitals. To be an evidence-based significant in one.13,15
There have been several clinical reports of the usetherapy, antibiotic-impregnated grafts should pass a
series of experimental and clinical evaluations (Table of rifampicin-bonded grafts for in situ replacement of
infected grafts.17–19 In situ replacement is appealing1). The rifampicin-bonded gelatin-coated Dacron graft
fulfils the criteria required to be assessed in clinical because it is often less technically demanding than
traditional graft excision with extra-anatomic re-trials (Table 1).5–12 The rifampicin is ionically bonded
to the gelatin coating of the graft. As the gelatin coating placement, particularly for aortic graft infection. In
vivo experimental studies showed that reinfection ratesis resorbed, the rifampicin is released over several
days into the surrounding tissues. were reduced using the rifampicin-bonded graft,20
though there were problems with MRSA infection.21There are three main indications for use of an anti-
biotic-impregnated graft: as a routine prophylaxis Results comparable to or better than those in historical
controls have been claimed in small-scale clinical re-against infection whenever prosthetic material is in-
serted; selectively in high-risk situations (such as the ports of in situ replacement with a rifampicin graft.
However, contemporary single centre results using theinsertion of a prosthetic graft through potentially in-
fected sites); and in situ replacement of established traditional approach of graft excision may be better
still.22 In the few reported series, recurrence of thegraft infection. These scenarios have been tested suc-
cessfully in a variety of experimental models.5–11 infection after in situ replacement was infrequent,
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Table 2. Randomised controlled trials of prophylactic rifampicin bonding.
Collected wound Two-year graft
complications infection rate
Italian Study13
Rifampicin 296 N/A 5 (1.7%)
Control 304 N/A 7 (2.3%)
European Study14
Rifampicin 1200 (2.9%) N/A
Control 1200 (4.4%) N/A
Joint Vascular Research Group Study15,16
Rifampicin 123 19 (15%) 6 (4.9%)
Control 134 28 (21%) 4 (3.0%)
though the Leicester group has reported problems and some Gram-negative pathogens. There was, how-
ever, no development of antibiotic resistance to ri-in infection with methicillin-resistant Staphylococcus
aureus (MRSA).19 No controlled trials, however, exist. fampicin by MRSA in an experimental study.23 The
increasing incidence in many units means that an
antibiotic active against MRSA would be preferable.
All the major studies have used rifampicin soaking at
a concentration of 1 mg/ml. There is in vivo evidenceThe Role of Antibiotic-bonded Vascular Grafts
that using 10 mg/ml is preferable.24
The results from the randomised trials of the first
clinically available antibiotic impregnated graft were
a disappointment, and run contrary to expectation if
the current theory of the aetiology of graft infection Conclusions
is correct. The question remains whether it is the
concept or the antibiotic delivery system that is in- Many surgeons now employ rifampicin-impregnated
grafts selectively in their clinical practice. It is ques-effective. Perhaps the mechanism of graft sepsis is
more complicated than originally thought. It is note- tioned whether use is now so routine that failure to
employ an antibiotic-impregnated graft in a high riskworthy that in the JVRG study, most infections oc-
curred in wounds that never healed properly; the situation could be culpable legally. The results of the
trials recorded no evidence of benefit, particularly foraetiology was probably extension of local sepsis and
the bacterial load may have been overwhelming.16 routine prophylaxis. Rifampicin is, however, relatively
cheap, and has so few side effects that many surgeonsThere may yet be a reduction in late graft infection
with low virulence bacteria, though the randomised feel more comfortable using it. Strachan has argued
for the use of antibiotic-impregnated grafts in patientsstudies will need to run for 5 to 10 years for this to
become evident. The study groups may become too at increased risk of infection, such as those with dia-
betes, distal skin necrosis or previous surgery.25 Hissmall by then: almost a third of the patients in the
JVRG trial had died before the 2-year follow-up.16 In consecutive clinical series has impressive results but
is uncontrolled. This author, using a rifampicin con-fact, all the studies are too small and the possibility
of a Type II (false negative) statistical error exists. It centration of 10 mg/ml, follows his pragmatic advice.
In situ replacement of infected grafts also remains awill take huge studies of any future grafts to prove
any advantage. The question of whether large scale popular option, though for this indication 60 mg/ml
rifampicin is preferable. The technique is, however,registries can be used as an alternative to randomised
trials to prove that antibiotic impregnated grafts are probably best avoided in patients with extensive per-
igraft sepsis.26effective remains open. Most scientists argue that re-
gistries are selective and therefore considerably in- In future, other antibiotic/antibacterial com-
binations, such as the silver graft27 and the Triclosanferior.
There is also the question of the most appropriate bonded graft,28 will become more widely available for
clinical use. They should undergo the same rigorousantibiotic. Rifampicin was identified as suitable more
by chance than design. Rifampicin has good activity testing procedures as outlined in Table 1. Vascular
surgeons should demand this information before beingagainst Gram-positive bacteria common in graft in-
fection, but has questionable activity against MRSA tempted by any theoretical advantages of a novel
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